Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorWestern University, Canada
About this trial
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial.
We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Eligibility criteria
Qualifiers
Adults aged 18 years or older
BMI; 35 kg/m²
10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis
Disqualifiers
Known contraindication to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, hypersensitivity)
Type 1 diabetes
No access to semaglutide via drug coverage
Pregnant, breastfeeding or planning to become pregnant
Trial design
Treatments tested in this trial
- Semaglutide
- Virtual Weight Management Coaching
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Western University, Canada
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborator
Queen Elizabeth II Health Sciences Centre
Collaborator
Unity Health Toronto
Collaborator
Source ClinicalTrials.gov